Specjalista neurolog. 1. Centrum Medyczne NEUROPROTECT 2. Centrum Kardiologii P?owiecka - Klinika 37
The aim of the #ACTT-1 (Adaptive Covid-19 Treatment Trial) published in The New England Journal of Medicine was evaluate the clinical #efficacy and #safety of #remdesivir among hospitalized adults with laboratory-confirmed #Covid19. In this study a total of 1062 patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. In the group treated with remdesivir median recovery time was shorter than in placebo gropu (10 days versus 15 days). In conclusion the data of this study show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. https://lnkd.in/eqgsh9h
